GlassScriptPhysician profile
James D Johns
NPI 1770589863
$7,073.10
in general payments reported to CMS, 2019-2025
36 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $924 · 2021: $1,251 · 2022: $829 · 2023: $976 · 2024: $1,088 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,999 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,999.09 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,171.08 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $748.28 | 2019-2025 | |
| Novo Nordisk INC | $659.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $617.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $469.59 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Astellas Pharma US INC | $442.99 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $440.20 | 2019-2021 | |
| Pfizer INC. | $372.71 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.45 | 2019-2024 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $329.23 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $300.53 | 2019-2022 | |
| Exact Sciences Corporation | $158.97 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $146.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $137.16 | 2019-2025 | |
| Esperion Therapeutics, INC. | $110.90 | 2023-2025 | Nexletol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $86.35 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $79.50 | 2021 | |
| Amgen INC. | $72.84 | 2019-2024 | Prolia, Evenity |
| Idorsia Pharmaceuticals US INC | $36.92 | 2022-2023 | Quviviq |
| Sumitomo Pharma America, INC. | $36.86 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.44 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.87 | 2019-2020 | |
| Allergan, INC. | $25.31 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.25 | 2025 | |
| Pharmacosmos Therapeutics INC. | $21.02 | 2024 | Monoferric |
| Alexion Pharmaceuticals, INC. | $20.16 | 2022 | |
| Inspire Medical Systems, INC. | $19.50 | 2025 | Inspire |
| Radius Health, INC. | $19.21 | 2025 | Tymlos |
| Vivus LLC | $14.62 | 2022 | |
| Seqirus USA INC | $14.49 | 2022 | |
| Cipher Pharmaceuticals US LLC | $14.04 | 2025 | Spinosad, Natroba |
| Cranial Technologies, INC | $13.55 | 2024 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $12.83 | 2019 | |
| Glaxosmithkline, LLC. | $12.31 | 2022 | |
| Alfasigma USA, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.